Monthly information on share capital and company voting rights
06 mai 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
06 mai 2024 02h00 HE
|
Cellectis Inc.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
02 mai 2024 16h30 HE
|
Cellectis Inc.
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
10 avr. 2024 16h30 HE
|
Cellectis Inc.
Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
08 avr. 2024 16h30 HE
|
Cellectis Inc.
Cellectis announces that preliminary data exploring novel TALEN® editing process in HSPCs will be presented at ASGCT 2024
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
17 nov. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
L’Assemblée Générale Extraordinaire de Cellectis se tiendra le 22 décembre 2023
17 nov. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, 17 nov. 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d’édition de génome...
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
06 nov. 2023 16h30 HE
|
Cellectis Inc.
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I...
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
01 nov. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
31 mai 2023 16h50 HE
|
Cellectis Inc.
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...